Oramed Pharmaceuticals Inc <ORMP.OQ> expected to post a loss of 2 cents a share - Earnings Preview
Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to show no change in quarterly revenue when it reports results on March 7 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Oramed Pharmaceuticals Inc is for a loss of 2 cents per share.
The one available analyst rating on the shares is "hold".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Oramed Pharmaceuticals Inc is $3.25, above its last closing price of $2.14.
This summary was machine generated March 5 at 21:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
[Reuters Analysis] Zelenskiy-Trump clash at White House sparks global rethink by US allies: Peter Apps
LONDON, March 7 (Reuters) - As they watched Ukrainian President Volodymyr Zelenskiy evicted from the White House last week after an unprecedented live televised quarrel with President Donald Trump and his Vice President JD Vance, some of America’s closest allies began to swiftly rea...
US Dollar Index falls to near 104.00 amid improved risk sentiment, US growth concerns
The US Dollar Index (DXY), which measures the US Dollar (USD) against six major currencies, is trading around 104.00 during the European hours on Thursday.
Stocks climb on bank earnings boost, US yields dip
NEW YORK (Reuters) -Global stocks rose on Friday, lifted by U.S. bank earnings, and on track for a weekly gain while U.S. Treasury yields were mostly lower after inflation and consumer confidence reports solidified expectations for the path of Federal Reserve rate cuts.
